Coverage
-
July 26, 2023
The U.S. Department of Justice will put Teva Pharmaceuticals in grave danger by pursuing more than $10 billion at an impending False Claims Act trial, amplifying the need for immediate First Circuit review of a question on kickbacks that has cleaved other appellate courts, the drugmaker said Wednesday.
1 other articles on this case.
View all »